Credit rating agency ICRA has revised the rating assigned to the Rs 5.0 crore fund based cash credit facilities of Anuh Pharma to BBB+ from LBBB. The outlook on the long term rating is stable. The rating agency has also revised the rating assigned to the Rs 5.0 crore short term fund based facilities and the Rs 30 crore non-fund based facilities to A2+ from A2. The short term fund based facilities are interchangeable with long term cash credit facilities.
The revision of ratings reflects the healthy growth in the company’s revenues and its strong financial profile underscored by its robust credit protection metrics and comfortable liquidity position.
Anuh Pharma, a part of the SK group of companies is a small-sized player in the API/bulk drug industry and is engaged in manufacturing products such as: erythromycin and its salts, higher macrolides like azithromycin, roxithromycin etc, pyrazinamide and chloramphenicol.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: